- Conditions
- Idiopathic Nephrotic Syndrome
- Interventions
- Standard of Care, UrApp
- Behavioral
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Minneapolis, Minnesota • Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1105–1128
of 9,377
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hip Fractures, Myocardial Injury
- Interventions
- Accelerated medical clearance and surgery
- Other
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 1,100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 23
- States / cities
- Chandler, Arizona • Davis, California • Irvine, California + 19 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Sorafenib (Nexavar, BAY43-9006), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 903 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 31
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 27 more
- Conditions
- GERD
- Interventions
- Aluvra™, Saline
- Device · Drug
- Lead sponsor
- Impleo Medical Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 10
- States / cities
- Los Angeles, California • Palo Alto, California • Englewood, Colorado + 7 more
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
- Interventions
- Trastuzumab (Herceptin), Pertuzumab, Echocardiography, Multigated Acquisition Scan, Mammography, Ultrasound, Magnetic Resonance Imaging, Biospecimen Collection, Questionnaire Administration
- Biological · Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,524 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2037
- U.S. locations
- 698
- States / cities
- Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 537 more
- Conditions
- Smoking Cessation
- Interventions
- placebo, Varenicline Tartarate
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 35 Years and older
- Enrollment
- 504 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 15 more
- Conditions
- Seasonal Allergic Rhinitis, SAR
- Interventions
- BDP HFA, Placebo nasal aerosol
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 715 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 45
- States / cities
- Oxford, Alabama • Bell, California • Costa Mesa, California + 40 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Ipilimumab, Oxaliplatin, Leucovorin, Fluorouracil, Irinotecan, Bevacizumab, Cetuximab, Nivolumab
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 839 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Sacramento, California • Denver, Colorado + 6 more
- Conditions
- Anxiety Disorders
- Interventions
- XBD173
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 16
- States / cities
- Anaheim, California • Los Angeles, California • Newport Beach, California + 13 more
- Conditions
- Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- Nivolumab, Sitravatinib, Docetaxel
- Biological · Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 577 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 133
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 109 more
- Conditions
- Ulcerative Colitis
- Interventions
- 75mg SHP647 (PF-00547659), 225mg SHP647 (PF-00547659)
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 29
- States / cities
- Scottsdale, Arizona • La Jolla, California • Orange, California + 26 more
- Conditions
- Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7, Stage IVB Uterine Corpus Cancer AJCC v7
- Interventions
- Carboplatin, Cisplatin, Doxorubicin Hydrochloride, Filgrastim, Laboratory Biomarker Analysis, Paclitaxel, Pegfilgrastim, Quality-of-Life Assessment
- Drug · Biological · Other
- Lead sponsor
- GOG Foundation
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2021
- U.S. locations
- 631
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 408 more
- Conditions
- Rectal Adenocarcinoma, Rectal Cancer
- Interventions
- High Rare Dose Rectal Brachytherapy Boost
- Radiation
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Rochester, New York • Portland, Oregon
- Conditions
- Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Interventions
- Tolvaptan
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,083 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 38
- States / cities
- Mobile, Alabama • Peoria, Arizona • Tempe, Arizona + 33 more
- Conditions
- Autism Spectrum Disorder
- Interventions
- Autism ALERT, Screening Intervention
- Other
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 12 Months to 54 Months
- Enrollment
- 148 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Prostate Cancer, Hormone Refractory Prostate Cancer
- Interventions
- MDV3100
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- Male only
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2018
- U.S. locations
- 9
- States / cities
- Boston, Massachusetts • New York, New York • Portland, Oregon + 2 more
- Conditions
- Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
- Interventions
- Cobimetinib, Olaparib, Onvansertib, Azenosertib, Saruparib, Tremelimumab
- Drug · Biological
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Fibromyalgia
- Interventions
- placebo, Xyrem®
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 573 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 71
- States / cities
- Auburn, Alabama • Birmingham, Alabama • Montgomery, Alabama + 61 more
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed, FIGO Stage III-IV, Partial Response, Complete Response
- Interventions
- Rucaparib, Nivolumab, Placebo Oral Tablet, Placebo IV Infusion
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,097 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 64
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Concord, California + 55 more
- Conditions
- Multiple Sclerosis
- Interventions
- Discontinuation of disease modifying therapy, Standard of Care
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 14 more
- Conditions
- Gastroesophageal Reflux
- Interventions
- Dexlansoprazole MR QD
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 178 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 52
- States / cities
- Hueytown, Alabama • Chandler, Arizona • Sierra Vista, Arizona + 49 more
- Conditions
- Rhinitis, Vasomotor
- Interventions
- GW685698X
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 38
- States / cities
- Beverly Hills, California • Huntington Beach, California • Mission Viejo, California + 34 more
- Conditions
- Shock, Traumatic
- Interventions
- 7.5% hypertonic saline/6% Dextran-70 (HSD), 7.5% hypertonic saline (HS), 0.9% normal saline
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 895 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • San Diego, California • Iowa City, Iowa + 5 more
- Conditions
- Myopia
- Interventions
- kalifilcon A, delefilcon A, senofilcon A
- Device
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 805 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 35
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Azusa, California + 31 more